A case of advanced renal cell carcinoma with peritoneal carcinomatosis responding to sorafenib therapy

Abstract

Peritoneal carcinomatosis is a relatively rare presentation of renal cell carcinoma. We report the case of an advanced renal cell carcinoma patient with peritoneal carcinomatosis who received sorafenib and achieved a dramatic and ongoing response in the metastatic lesion. After 6 months of sorafenib administration, despite a CT scan showing a stable left renal mass, the patient had marked shrinkage of the peritoneal nodules and ascites had disappeared. To our knowledge, this is the first report showing therapeutic activity of sorafenib against peritoneal carcinomatosis in a patient with renal cell carcinoma.

Omental Nodular Deposits of Recurrent Chromophobe Renal Cell Carcinoma Seen on FDG-PET/CT

“…Our patient was treated with sunitinib, a tyrosine kinase inhibitor, which has been proven to be effective for peritoneal carcinomatosis. [ 7 ]…”

Leukemoid Reaction and Malignant Ascites in a Renal Carcinoma with Sarcomatoid Differentiation. Unusual Case Report and Literature Review

“…The extension to the peritoneum, is associated with poor prognosis [11]. Initial expression of this type of cancer by ascites, is even more uncommon [12]. However, it is known that this kind of metastases, happens frequently in sarcomatoid tumors [9].…”

“…However, it is known that this kind of metastases, happens frequently in sarcomatoid tumors [9]. Development of metachronous metastases in omentum is considered extremely rare in international literature [12] [13]. Paraneoplastic syndromes are systemic manifestations of a malignant tumor with no relation with its metastatic activity.…”